Lara Pizzorno is the author of “Your Bones: How You Can Prevent Osteoporosis and Have Strong Bones for Life – Naturally” and a member of the American Medical Writers Association with 29 years of experience specializing in bone health.
Recently we asked Lara if she would help us provide a series of short, ongoing videos to help you (our customers and readers) stay up to date on the latest facts and science related to bone health and overcoming osteoporosis naturally.
In this latest video, Lara discusses the latest strontium research – both for strontium ranelate and strontium citrate. Watch the video below (or read the transcript provided) and let us know what you think in the comments. 🙂
Hello, my name is Lara Pizzorno the author of “Your Bones” and I am here today to share some information with you about the latest research on strontium. Both the natural form of strontium which is strontium citrate, that’s available as a supplement and also the unnatural form of strontium, strontium ranelate, which is still being prescribed in the European Union although with lots of restrictions now.
So if you’ve read “Your Bones” or if you’ve seen my blog post on strontium on AlgaeCal’s website than you already know that I recommend and personally benefitted from using the natural form of strontium, strontium citrate, which AlgaeCal provides in its Strontium Boost supplement. But I do not recommend and would never personally use: the drug form of strontium which is called strontium ranelate and it continues to be prescribed although now with further restrictions because it is so potentially harmful. In Europe where it’s sold under its trade names Protelos and Osseor.
So in this video, I would like to update you about the latest research on both forms of strontium. The natural form, strontium citrate and the unnatural form, strontium ranelate. And I’d like to start with the drug form first.
On January 13th on 2014, The European Medicines Agency Pharmacovigilance Risk Assessment Committee, recommended strontium ranelate which I mentioned is sold under the names of Protelos and Osseor should not longer be approved by them to treat osteoporosis because this is a drug that people can get insurance cover for in the European Union still, unfortunately. Back in April of 2013 the European Medicines Agency had first recommended severely restricting the use of Protelos and Osseor because both have been strongly associated with increased risk of heart problems. But in 2014 they questioned even how well the severe restrictions they put in place in April of 2013 were going to work to reduce cardiovascular risk in patients prescribed these drugs and how well they can actually be working in clinical practice in other words real life. So the Pharmacovigilance Risk Assessment Committee went on to conduct an in depth review on the benefits of strontium ranelate and what they found out was, they didn’t really have very many. They found that out of every 1000 patient years there were 4 more cases of heart problems, including heart attacks and 4 more cases of blood clots or blockages of blood vessels with strontium ranelate than with placebo and they also found that strontium ranelate was clearly associated with a number of other risks including very serious skin reactions that demanded hospitalization, disturbances in consciousness, seizures, hepatitis, which is liver inflammation and a reduction of blood cells being produced in bone marrow. Our blood cells get produced in blood marrow so this adverse effect is particularly disquieting.
With regards to its benefits the Pharmacovigilance Risk Assessment Committee found that strontium ranelate has only been shown to have very modest benefits in osteoporosis.
In every 1000 patient years, which is the equivalent of 1000 patients being treated for a year, strontium ranelate may and I emphasis may, not for sure, prevent possibly 5 non spinal fractures, 15 nonvertebral fractures and less than half of one hip fracture, so 60% of your bone can break but the other 40% strontium ranelate will cover you – not too terrific.
Pharmacovigilance Risk Assessment Committee weighed these meager benefits against strontium ranelate’s known risks and concluded the balance was not favorable. So they recommended that strontium ranelate be suspended and this recommendation was send to the Agency’s Committee for Medicinal Products of Human Use, which reviewed everything again and issued a final opinion at its meeting on January 20-23 in 2014. So if you know about the money,power and political influence that is wielded by Big Pharma, you probably will not be surprised to hear that despite everything: poor results, lots of adverse effects and high costs, this is not an inexpensive drug, Protelos/ Osseor (strontium ranelate) continues to be authorized in the European Union to treat severe osteoporosis. But it has very severe restrictions. It cannot be prescribed to patients that cannot be treated by any other medicine approved for osteoporosis, patients who have a heart of circulatory problems may not use the medicine, before starting treatment doctors much assess patients risk of heart disease and high blood pressure and must continue to check their intervals while the patient is using this drug. Strontium ranelate cannot be prescribed to anyone who has had any kind of heart or circulatory problems and its treatment must be stopped if the person develops ischemic heart disease, peripheral arterial disease or cerebrovascular disease or uncontrolled high blood pressure. Big surprise. Well the final European Medicine Agency’s recommendation was based on an analysis of pooled data from randomized study in 7500 postmenopausal women with osteoporosis. The results of this huge study showed a 60% increase in risk of heart attack from strontium ranelate compared to placebo with a relative risk increase ranging from 1.07-2.38. In other words a 7% to 238% increase in risk and a 50% increased risk of deep blood clot formation, in other words venous thrombotic and embolic events. The increased of risk here ranged from 1.04- 2.19 so a little bit over 100% to over 220% increase in risk.
In Croatia, HOMED, which is their agency for medicinal products and medical devices had already removed strontium ranelate for sale after they received 24 very significant adverse reaction reports. 7 of which were related to skin, 7 were neurological and 1 was a blood adverse reaction. Out of these 24 reports, 9 of them were considered very very serious and among these, 3 were related to heart adverse reactions, atrial fibrillation, premature heart contraction and arrhythmias and 2 to severe skin reactions, so severe that they caused hospitalization and people can suffocate when their face swells really quickly. So strontium ranelate is no longer approved for sale in Croatia but you can still get it in the European Union.
Now for the really good news, these severe reactions and all the restrictions on strontium ranelate use have finally driven researchers to take a look at strontium citrate, the natural form of strontium, which has never been shown to cause the adverse reactions caused by strontium ranelate and its beneficial effects were the reason that strontium ranelate was created. It was created in the laboratory for one reason only, so that a natural substance could be patented, more money could be made on it.
So the first new paper that came out on strontium citrate, the natural form, reported on bone levels of strontium on a woman volunteer, who had been recruited in December of 2008 as part of the Ryerson-McMaster University Strontium and Bone Research Study. This is a large ongoing study that’s been continuing for a number of years now. And this woman’s bone strontium levels were measured twice weekly, weekly and then monthly intervals. She was given strontium citrate supplements at 680 mg per day which is the same thing that you get with Strontium Boost. And an increase in her strontium levels in her bone were began to be seen after just 24 hours. Increases continued to be seen at each measurement interval with the most recent, which was taken after 800 days, which showed incorporation of strontium at the finger and ankle, they measured there because it’s easy to see the measurement of cortical and trabecular bone and they were 7 and 15x higher than the baseline reading.
What’s important about these results is that they show that strontium incorporation into bone and its retention into bone does not plateau in 2-3 years but continues to increase over time.
The next study to be published in bone, came out in January 2013 and it was an animal study a rat study and the objective was to quantify bone strontium accumulation in female spread dawley rats who were administered strontium citrate and compare these levels to rats that were given strontium ranelate the drug or placebo over the period of 8 weeks. Bone strontium levels in rats that were administered strontium citrate were found to be significantly greater than the bone strontium levels of rats that were given strontium ranelate or placebo. This was partly due to the finding that strontium citrate provided a greater amount of elemental strontium than did strontium ranelate. When this was factored into the analysis, differences in bone strontium levels between the rats receiving strontium citrate versus those getting the natural drug strontium ranelate form weren’t quite as wide, but both forms of strontium resulted in very significant increases of bone strontium levels and strontium citrate did a better job delivering strontium to bone than strontium ranelate.
The next paper to be published in bone just came out this past January so January 2014, this was a human study and it involved 10, 9 of whom had osteopenia or osteoporosis. These 10 volunteers were again recruited by the large ongoing Ryerson and McMaster University Strontium and Bone Research Study and they agreed to have their bone strontium levels measured as they self supplemented with strontium supplements of their choice. Not surprisingly, they all chose to use strontium citrate supplements. Levels of strontium in their fingers and ankles to represent cortical and trabecular bone were measured using X-ray fluorescence and the baseline readings represented their natural bone strontium levels before strontium supplementation, since all volunteers had no prior intake of strontium supplements or medications. Once strontium supplements were started, a 24 hour reading was taken followed by frequent measurement ranging from weekly to biweekly to monthly. The longest volunteer participant was 1535 days or 4 years. So after just the first 24 hours, average strontium signals began to rise in these women and bone strontium levels continued to increase throughout the study, indicating that bone strontium levels will continue to rise in bone even after 4 year of strontium supplement intake. Interestingly, the strontium signal varied widely between these individual women, so much so that after 3 years the highest strontium signal observed averaged 28 for the finger and 26 for the ankle in one volunteer, compared to just 3 and 4.5 for the finger and ankle in another volunteer.
So what does this mean?
Well, as I keep saying, each of us is unique! Not everyone is going to benefit from every single thing and in exactly the same way, but some will benefit greatly from strontium citrate and some will benefit a little less but the key point here is that everyone benefited (you can read about the science-backed benefits of strontium here). Importantly, unlike strontium ranelate, not a single adverse effect was reported in any of the participants in this 4 year study using strontium citrate. So I hope this encourages you that if you’re not using strontium citrate as part of your bone building program, to consider it and discuss it with your doctor and I hope the information has helped and I hope you’ll tune in next time. Thanks, bye!
If you want to learn more about strontium after watching Lara’s video, head to our dedicated strontium page.
European Medicines Agency’s Pharmacovigilance Risk Assessment Committee findings regarding strontium ranelate:
Moise H, Adachi JD, Chettle DR, et al. Monitoring bone strontium levels of an osteoporotic subject due to self-administration of strontium citrate with a novel diagnostic tool, in vivo XRF: a case study. Bone. 2012 Jul;51(1):93-7. doi: 10.1016/j.bone.2012.04.008. Epub 2012 Apr 23. PMID: 22549020
Wohl GR, Chettle DR, Pejović-Milić A, et al. Accumulation of bone strontium measured by in vivo XRF in rats supplemented with strontium citrate and strontium ranelate. Bone. 2013 Jan;52(1):63-9. doi: 10.1016/j.bone.2012.09.002. Epub 2012 Sep 17. PMID: 22995463
Moise H, Chettle DR, Pejović-Milić A. Monitoring bone strontium intake in osteoporotic females self-supplementing with strontium citrate with a novel in-vivo X-ray fluorescence based diagnostic tool. Bone. 2014 Apr;61:48-54. doi: 10.1016/j.bone.2014.01.002. Epub 2014 Jan 14. PMID: 24434614